Table 3

Sensitivities and specificities of the Vidas and Liaison EBNA IgG assaysa

Expected EBV status in referenced assayVidas EBNA IgGLiaison EBNA IgGLiaison minus Vidas (%) (95% CI)
Sensitivity or specificity (%)b (95% CI)False neg or pos (no.)Eq (no.)Sensitivity or specificity (%)b (95% CI)False neg or pos (no.)Eq (no.)
Past infectionc (n = 164)95.7 (92.6–98.8)5292.0 (87.8–96.2)85−3.7 (−7.76 to −0.44)*
Primary infection (n = 186)95.6 (92.6–98.6)5356.8 (49.7–63.9)2455−38.8 (−46.12 to −31.15)*
EBV seronegative (n = 157)97.5 (95.1–99.9)2294.3 (90.7–97.9)09−3.2 (−8.29 to 1.57)
Total (n = 343)d96.5 (94.5–98.5)7574.2 (69.5–78.5)2464−22.3 (−27.48 to −17.31)*
  • a False neg or pos, false negative (with past infection samples) or false positive (with primary infection and EBV-seronegative samples); no., number of samples; Eq, equivocal (considered false positive for specificity and false negative for sensitivity); CI, confidence interval; *, statistically significant.

  • b Percentages for samples from patients with primary infection and EBV-seronegative samples are percent specificities. Percentages for the other samples are percent sensitivities.

  • c For past infection data, samples with isolated VCA IgG antibodies were not included.

  • d Totals for Primary infection and EBV seronegative results.